Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Wesson W"'
Autor:
Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Wesson W; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Lutfi F; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Porter DL; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Bachanova V; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX., Perales MA; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY., Maziarz RT; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Brower J; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Shah GL; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chen AI; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Oluwole OO; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN., Schuster SJ; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Bishop MR; David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Riedell PA; David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5346-5354.
Autor:
Khaliq A; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS., Wesson W; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS., Logan E; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS., Tabak C; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS., Mushtaq MU; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; US Myeloma Innovations Research Collaborative, Westwood, KS., Lin T; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Baranda J; Department of Medicine, University of Kansas Medical Center, Kansas City, KS., Shune L; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative, Westwood, KS., Abdallah AO; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative, Westwood, KS., McGuirk J; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Hamadani M; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Ahmed N; Department of Medicine, University of Kansas School of Medicine, Kansas City, KS; Division of Hematologic Malignances and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Department of Medicine, University of Kansas Medical Center, Kansas City, KS; US Myeloma Innovations Research Collaborative, Westwood, KS. Electronic address: nahmed5@kumc.edu.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct; Vol. 24 (10), pp. e344-e349. Date of Electronic Publication: 2024 May 31.
Autor:
Wesson W; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas. Electronic address: wwesson@kumc.edu., Dima D; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Cleveland Clinic Foundation, Cleveland, Ohio., Suleman N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas., Saif MSI; Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, Kansas., Tabak C; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas., Logan E; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas., Davis JA; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina., McGann M; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina., Furqan F; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin., Mohan M; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin., Rashid A; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas., Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas., Ullah F; Cleveland Clinic Foundation, Cleveland, Ohio., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas., Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas., Raza S; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Cleveland Clinic Foundation, Cleveland, Ohio., McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas., Hamadani M; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin., Anwer F; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Cleveland Clinic Foundation, Cleveland, Ohio., Hashmi H; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas; Department of Medicine, Multiple Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas; U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep; Vol. 30 (9), pp. 876-884. Date of Electronic Publication: 2024 Jun 11.
Autor:
Alsouqi A; Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Ahmed G; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Wang J; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Cassanello G; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Oncology and Onco-hematology, University of Milan, Milan, Italy., Szabo A; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Rojek AE; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA., Riedell PA; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA., Awan F; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Samples L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Hu M; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA., Wesson W; Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Cancer Center, Kansas City, Kansas, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Cancer Center, Kansas City, Kansas, USA., Iqbal M; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA., Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA., Scordo M; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Johnson PC; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA., Ito S; Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Hamadani M; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Frigault M; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1624-1627. Date of Electronic Publication: 2024 May 20.
Publikováno v:
Blood [Blood] 2024 Jun 27; Vol. 143 (26), pp. 2681-2682.
Autor:
Wesson W; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Tabak C; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Logan E; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Marchena-Burgos J; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Nelson M; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Davis JA; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA., McGann M; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA., Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Hoffmann M; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Hashmi H; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
Publikováno v:
European journal of haematology [Eur J Haematol] 2024 Apr; Vol. 112 (4), pp. 538-546. Date of Electronic Publication: 2023 Dec 03.
Autor:
Thurlapati A; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA.; These authors contributed equally to the creation of the manuscript., Wesson W; University of Kansas School of Medicine, Kansas City, KS 66103, USA.; These authors contributed equally to the creation of the manuscript., Davis JA; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Gaffney KJ; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Weeda E; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Velayati A; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA., Bakos JK; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA., Granger K; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Smith D; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Maldonado AP; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Herrington T; Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA., Potts J; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA., Hashmi H; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA.
Publikováno v:
Journal of hematology [J Hematol] 2023 Dec; Vol. 12 (6), pp. 243-254. Date of Electronic Publication: 2023 Dec 09.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Davis JA; Department of Pharmacy, Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina., Sborov DW; Divison of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Wesson W; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas, Missouri., Julian K; Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas, Missouri., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas, Missouri., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas, Missouri., Hashmi H; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina. Electronic address: hashmih@musc.edu.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2023 Sep; Vol. 29 (9), pp. 567-571. Date of Electronic Publication: 2023 May 22.
Autor:
Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Wesson W; School of Medicine, University of Kansas, Kansas, KS, United States., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Bansal R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., AbdelHakim H; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Bromert S; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Appenfeller A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Ghazal BA; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Singh A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Abhyankar S; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Ganguly S; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States.; Mary and Ron Neal Cancer Center, Houston Methodist Hospital, Houston, TX, United States., McGuirk J; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States., Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, United States.
Publikováno v:
Frontiers in oncology [Front Oncol] 2023 Aug 03; Vol. 13, pp. 1206715. Date of Electronic Publication: 2023 Aug 03 (Print Publication: 2023).